Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Chikungunya Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : National Institutes of Health
Deal Size : $18.0 million
Deal Type : Funding
Details : The funding will be used to develop a temperature stable, single-dose vaccine candidate, a dried (lyophilized) formulation, for the chikungunya virus by using AAHI’s innovative RNA platform technology.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
March 08, 2023
Lead Product(s) : Chikungunya Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : National Institutes of Health
Deal Size : $18.0 million
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Defense Innovation Unit
Deal Size : $3.0 million
Deal Type : Funding
Details : AAHI will be working with the DIU and JPM CBRN Medical to develop a prototype nasal spray using AAHI’s novel formulation of two adjuvants, substances that enhance immune responses.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 15, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Defense Innovation Unit
Deal Size : $3.0 million
Deal Type : Funding
Lead Product(s) : AAHI-SC2 Self-amplifying RNA COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Preclinical studies published in NPJ Vaccines demonstrate the ability of AAHI’s unique AAHI-SC2, SARS-CoV-2 self-amplifying RNA vaccine, to elicit strong antibody and T cell immunity to multiple variants of SARS-CoV-2.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
February 11, 2022
Lead Product(s) : AAHI-SC2 Self-amplifying RNA COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ID93+GLA-SE Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : Quratis Co., Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 2a Clinical Trial of ID93+GLA-SE Vaccine in BCG-vaccinated Healthy Healthcare Workers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
January 16, 2019
Lead Product(s) : ID93+GLA-SE Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : Quratis Co., Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : H5 VLP
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Medicago | Defense Advanced Research Projects Agency
Deal Size : Inapplicable
Deal Type : Inapplicable
H5-VLP + GLA-AF Vaccine Trial in Healthy Adult Volunteers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 06, 2012
Lead Product(s) : H5 VLP
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Medicago | Defense Advanced Research Projects Agency
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
